Adjuvant Interferon in High-Risk Melanoma: The AIM HIGH Study—United Kingdom Coordinating Committee on Cancer Research Randomized Study of Adjuvant Low-Dose Extended-Duration Interferon Alfa-2a in High-Risk Resected Malignant Melanoma

Hancock, Barry W.; Wheatley, Keith; Harris, Syed Hasan; Ives, Natalie; Harrison, G.; Horsman, Janet; Middleton, Mark R.; Thatcher, Nick; Lorigan, Paul; Marsden, J.R.; Burrows, Lara J.; Gore, Martin

doi:10.1200/jco.2004.03.185

Cited by 213 publications

(84 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several other prospective randomized trials examined interferon-α2b at a variety of doses and treatment schedules in patients with high-risk stage II melanoma, but none has demonstrated a survival benefit. [19][20][21][22] These studies are complicated by a lack of a standardized definition of 'high-risk' , 23 different interferon-α2b doses and schedules, and in some cases include other drugs in combination. Figure 1 | Stage II melanoma immunotherapy treatment algorithm.…”

Section: Literature Review and Analysismentioning

confidence: 99%

The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma

et al. 2013

View full text Add to dashboard Cite

| Immunotherapy is associated with durable clinical benefit in patients with melanoma. The goal of this article is to provide evidence-based consensus recommendations for the use of immunotherapy in the clinical management of patients with high-risk and advanced-stage melanoma in the USA. To achieve this goal, the Society for Immunotherapy of Cancer sponsored a panel of melanoma experts-including physicians, nurses, and patient advocates-to develop a consensus for the clinical application of tumour immunotherapy for patients with melanoma. The Institute of Medicine clinical practice guidelines were used as a basis for this consensus development. A systematic literature search was performed for high-impact studies in English between 1992 and 2012 and was supplemented as appropriate by the panel. This consensus report focuses on issues related to patient selection, toxicity management, clinical end points and sequencing or combination of therapy. The literature review and consensus panel voting and discussion were used to generate recommendations for the use of immunotherapy in patients with melanoma, and to assess and rate the strength of the supporting evidence. From the peer-reviewed literature the consensus panel identified a role for interferon-α2b, pegylated-interferon-α2b, interleukin-2 (IL-2) and ipilimumab in the clinical management of melanoma. Expert recommendations for how to incorporate these agents into the therapeutic approach to melanoma are provided in this consensus statement. Tumour immunotherapy is a useful therapeutic strategy in the management of patients with melanoma and evidence-based consensus recommendations for clinical integration are provided and will be updated as warranted.

show abstract

Section: Literature Review and Analysismentioning

confidence: 99%

The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma

et al. 2013

View full text Add to dashboard Cite

show abstract

“…The greatest benefit was observed in patients with micrometastases detected by the sentinel node biopsy, while the patients with palpable lymph nodes did not have any benefits (Eggermont et al, 2008). Several studies with small doses of IFN showed the effect to DFS Pehamberger et al, 1998;Cameron et al, 2001;Kirkwood et al, 2000;Hancock et al, 2004), of which, only one showed significant importance for OS . On the other hand, the WHO-16 study, which tested low doses of IFN in duration of 3 years in patients in stadiums IIIB and IIIC, did not show any significant effect to DFS or OS (Cascinelli et al, 2001).…”

Section: Radiotherapy Of Melanoma In Pregnancymentioning

confidence: 99%

Melanoma During Pregnancy

Popović¹,

Grgić²,

Popović³

2011

Advances in Malignant Melanoma - Clinical and Research Perspectives

View full text Add to dashboard Cite

“…They speculate that this could be a result of patients having died of other causes, but there have been no data presented to support this. The general 540 Letter to the Editor The Oncologist ® consensus of the melanoma field [2][3][4][5][6] is that these trials demonstrated a small improvement in time to relapse but that individually, in a pooled analysis by Kirkwood and colleagues [7], in an independent review [4], and in a meta-analysis [3], these trials have not provided evidence for an improvement in overall survival.…”

Section: Disclosure Of Potential Conflicts Of Interestmentioning

confidence: 99%

Response to “Helping Melanoma Patients Decide Whether to Choose Adjuvant High-Dose Interferon-α2b”

et al. 2006

View full text Add to dashboard Cite

Adjuvant Interferon in High-Risk Melanoma: The AIM HIGH Study—United Kingdom Coordinating Committee on Cancer Research Randomized Study of Adjuvant Low-Dose Extended-Duration Interferon Alfa-2a in High-Risk Resected Malignant Melanoma

Abstract: The results from this study, taken in isolation, do not indicate that extended-duration low-dose interferon is significantly better than observation alone in the initial treatment of completely resected high-risk malignant melanoma.

Cited by 213 publications

References 25 publications

The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma

The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma

Melanoma During Pregnancy

Response to “Helping Melanoma Patients Decide Whether to Choose Adjuvant High-Dose Interferon-α2b”

Contact Info

Product

Resources

About